Vyleesi Cost in Michigan 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Vyleesi and Why Does Cost Vary So Much in Michigan?

Vyleesi (bremelanotide) is the only FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved Vyleesi on June 21, 2019, making it one of just two approved pharmacological treatments for HSDD alongside flibanserin (Addyi). Cost in Michigan varies by route of access: brand retail, insurance with PA, Michigan Medicaid, manufacturer savings programs, or compounded versions from a licensed 503A pharmacy.

The price gap between brand and compounded versions is large. At roughly $1,200 per month for brand Vyleesi and approximately $140 per month for compounded bremelanotide at a licensed Michigan 503A pharmacy, the difference exceeds $12,700 annually. That gap is why understanding every available access pathway matters for Michigan patients.

The key RECONNECT trials, published in Obstetrics and Gynecology in 2019 (N=1,247 premenopausal women across two randomized controlled trials), demonstrated that bremelanotide significantly increased satisfying sexual events and reduced distress scores versus placebo [1]. Those data supported the FDA label, which restricts use to premenopausal women with HSDD not caused by a medical condition, relationship problem, or medication [2].

Brand Vyleesi Price in Michigan in 2026

The manufacturer wholesale acquisition cost for Vyleesi is approximately $1,200 per month. Michigan retail pharmacies, including large chains like CVS and Walgreens, generally price it at or near that list price without insurance. A single carton contains four 1.75 mg auto-injectors, one for each anticipated sexual encounter during the billing cycle.

Cash-pay patients in Michigan should check GoodRx and NeedyMeds before paying list price at the counter, though savings at retail for Vyleesi are modest compared to generics. The FDA label notes that nausea is the most common adverse effect, occurring in approximately 40% of participants in the RECONNECT trials, sometimes requiring ondansetron co-prescription, which adds to total monthly cost [1].

Palatin Technologies, the maker of Vyleesi, maintains a patient assistance program. Commercially insured patients who qualify may pay as little as $0 per month through the savings card; the program has income and insurance eligibility restrictions. Michigan patients can enroll at the Vyleesi website or ask their prescriber's office for a savings card at the point of prescribing.

For patients without commercial insurance who fall below income thresholds, Palatin's patient assistance program may provide Vyleesi at no cost. Patients should contact Palatin directly, as income cutoffs and enrollment periods shift year to year.

Michigan Medicaid Coverage for Vyleesi

Michigan Medicaid covers Vyleesi for eligible premenopausal women with HSDD, but requires prior authorization (PA). This is consistent with how Michigan's Medicaid pharmacy benefit manages specialty and brand-only products. The PA process typically requires documentation of the HSDD diagnosis, confirmation of premenopausal status, absence of a contributing medical cause or medication, and often a statement that psychotherapy or couples counseling has been considered or attempted.

The American College of Obstetricians and Gynecologists (ACOG) published guidance noting that HSDD affects an estimated 8 to 10 percent of women and represents a clinically significant condition warranting treatment consideration, which strengthens the clinical rationale in PA submissions [3]. Prescribers filing a PA for Michigan Medicaid should include DSM-5 diagnostic criteria documentation and rule-out notes for secondary causes.

Michigan Medicaid managed care plans, including Molina Healthcare of Michigan, Blue Cross Complete, and McLaren Health Plan, each administer their own PA forms, but all operate under Michigan Department of Health and Human Services (MDHHS) pharmacy policy. Approval timelines typically run 3 to 14 business days. Denials can be appealed; the first step is a peer-to-peer review between the prescriber and the plan's medical director.

Dual-eligible patients (Medicare and Medicaid) face a different pathway. Medicare Part D generally does not cover Vyleesi because it falls outside the Part D covered drug categories for sexual dysfunction. Dual-eligible Michigan patients should work with their Medicaid managed care plan rather than their Part D plan.

Compounded Bremelanotide in Michigan: Legality and Cost

Compounded bremelanotide is legal in Michigan when dispensed by a pharmacy licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound for individual patient prescriptions and do not distribute across state lines to the general public [4]. Michigan has several state-licensed compounding pharmacies that prepare bremelanotide as a subcutaneous injection, typically at concentrations matching the FDA-approved 1.75 mg per dose.

Cost at a licensed Michigan 503A pharmacy runs approximately $140 per month, compared to the $1,200 brand list price. That $1,060 monthly difference makes compounding the primary access route for many cash-pay patients in Michigan.

The FDA maintains that compounded versions of FDA-approved drugs should be reserved for patients with a documented clinical need that the approved product cannot meet, such as an allergy to an excipient in the brand formulation [5]. Prescribers and patients should discuss this distinction. Michigan's Board of Pharmacy enforces state compounding pharmacy standards, and patients can verify a pharmacy's license status through the Michigan Department of Licensing and Regulatory Affairs (LARA) online lookup tool.

503B outsourcing facilities, which compound in bulk without individual patient prescriptions, are not permitted to compound copies of FDA-approved drugs like Vyleesi under current federal law [5]. This means any Michigan patient receiving compounded bremelanotide should confirm their pharmacy holds a 503A designation, not a 503B designation.

Telehealth platforms operating in Michigan, including HealthRX, can prescribe bremelanotide. The prescription can then be sent to the patient's pharmacy of choice, including a licensed 503A compounding pharmacy, for dispensing.

Which Michigan Insurance Plans Cover Vyleesi?

Commercial coverage for Vyleesi in Michigan is inconsistent across plans. Blue Cross Blue Shield of Michigan, Priority Health, and HAP (Health Alliance Plan) each maintain their own formularies, and Vyleesi's placement changes with annual formulary updates. Most plans that cover it place it on a specialty tier requiring PA.

The Endocrine Society's clinical practice guideline on female sexual dysfunction, updated in 2019, recognizes bremelanotide as a treatment option for premenopausal HSDD, which provides prescribers with authoritative backing when appealing insurance denials [6]. Citing this guideline directly in the PA letter or appeal letter may increase approval rates.

Patients should request a formulary exception if Vyleesi is not on their plan's formulary. Michigan law requires insurers to have a formulary exception process for medically necessary drugs not on the formulary. The prescriber submits clinical documentation; the insurer must respond within 72 hours for non-urgent requests and 24 hours for urgent ones under Michigan Insurance Code provisions.

Employer-sponsored self-insured plans are governed by ERISA and are not subject to Michigan state insurance mandates, which means their formulary exception processes may differ. Patients on self-insured plans should check with their HR department or plan administrator directly.

Telehealth Prescribing of Vyleesi in Michigan

Michigan allows telehealth prescribing of Vyleesi. Prescribers licensed in Michigan can conduct an audio-video evaluation, confirm the HSDD diagnosis using validated tools like the Female Sexual Distress Scale-Revised (FSDS-R), and issue a prescription without an in-person visit [7]. The prescription then routes to a local retail pharmacy or a licensed 503A compounding pharmacy.

The North American Menopause Society (NAMS) 2022 position statement on sexual health supports the use of telehealth for sexual medicine evaluations when appropriate clinical infrastructure exists [8]. Michigan's telehealth parity law requires that commercial insurers reimburse telehealth visits at parity with in-person visits for covered services, which can reduce the cost of the initial evaluation visit.

HealthRX clinicians licensed in Michigan can evaluate patients for HSDD, administer the FSDS-R and the Female Sexual Function Index (FSFI) screening instruments, and prescribe bremelanotide where clinically appropriate. Patients should have had a recent gynecologic evaluation to rule out secondary causes of low desire before starting bremelanotide.

How Bremelanotide Works: A Brief Clinical Summary

Bremelanotide is a cyclic heptapeptide that acts as a nonselective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Its primary mechanism for increasing sexual desire appears to involve MC4R activity in the hypothalamus [9]. This is a central nervous system mechanism, distinct from hormonal treatments like testosterone, which acts peripherally.

The RECONNECT trials tested bremelanotide 1.75 mg subcutaneous injection administered on an as-needed basis up to once per 24 hours and no more than once per 24 hours [1]. Across both trials, bremelanotide-treated women reported a statistically significant increase in satisfying sexual events (P<0.001 versus placebo) and a statistically significant decrease in FSDS-R distress scores at 24 weeks [1]. The trials enrolled women aged 18 to 55 with a confirmed HSDD diagnosis using DSM-IV-TR criteria for hypoactive sexual desire disorder or DSM-5 criteria for female sexual interest/arousal disorder.

Nausea affected approximately 40% of participants, flushing affected about 20%, and transient blood pressure increases of 6 mmHg systolic and 3 mmHg diastolic were observed within 12 hours of dosing [2]. The FDA label carries a warning against use in patients with cardiovascular disease for this reason [2].

The RECONNECT Trial Data Every Michigan Patient Should Know

The two RECONNECT phase 3 trials are the clinical foundation for bremelanotide's approval. Trial 1 enrolled 628 women; Trial 2 enrolled 619 women. Both trials ran 24 weeks and used a placebo-controlled, double-blind design [1].

In Trial 1 to 24.5% of bremelanotide-treated women achieved a clinically meaningful improvement on the FSDS-R Item 13 (distress about low sexual desire) versus 16.5% on placebo [1]. In Trial 2 to 25.3% of bremelanotide-treated women achieved this threshold versus 17.0% on placebo [1]. These responder rates are modest but statistically significant, and they reflect the heterogeneous nature of HSDD etiology.

The North American Menopause Society noted in its 2022 position statement that both approved HSDD medications (flibanserin and bremelanotide) show modest effect sizes in trials, and patient selection and counseling are important factors in treatment outcomes [8]. Patients with HSDD related to relationship distress or trauma are less likely to respond to pharmacotherapy alone.

Choosing Between Brand Vyleesi, Compounded Bremelanotide, and Flibanserin in Michigan

Michigan patients with HSDD have three main pharmacological options in 2026: brand Vyleesi, compounded bremelanotide from a 503A pharmacy, and flibanserin (Addyi), which is also FDA-approved for HSDD in premenopausal women [10]. Each has a distinct profile.

Brand Vyleesi costs approximately $1,200 per month without insurance. It is used as needed, which some patients prefer over daily dosing. Flibanserin requires daily oral dosing and carries alcohol interaction warnings; generic flibanserin became available after patent expiration and may cost significantly less than brand Addyi at Michigan retail pharmacies [10].

Compounded bremelanotide at a licensed Michigan 503A pharmacy costs approximately $140 per month and mirrors the brand's subcutaneous injection format. The trade-off is that compounded drugs lack FDA manufacturing oversight, though licensed compounding pharmacies must meet USP 797 sterility standards for injectable preparations [5].

For cost-conscious Michigan patients with no insurance coverage, the decision tree typically runs as follows: check eligibility for the Palatin savings card first; if ineligible, compare 503A compounded bremelanotide at $140 per month with generic flibanserin pricing at local pharmacies; if Michigan Medicaid applies, pursue the PA process before paying out of pocket.

The AACE (American Association of Clinical Endocrinologists) and the Endocrine Society both recommend addressing modifiable contributors to HSDD, including thyroid dysfunction, depression, relationship factors, and medications such as SSRIs, before or alongside pharmacotherapy [6]. A TSH level and medication review at the initial visit may prevent unnecessary prescribing.

Practical Steps for Michigan Patients Starting Vyleesi in 2026

Getting started with bremelanotide in Michigan involves five concrete steps. First, schedule an evaluation, in person or via telehealth, with a prescriber licensed in Michigan who can administer validated HSDD screening tools. Second, confirm insurance coverage or choose a cash-pay route before the prescription is written; changing pharmacy after the prescription is sent can cause delays. Third, if pursuing Michigan Medicaid, ask the prescriber's office to initiate the PA at the time of visit, not after. Fourth, check the Palatin Technologies savings card eligibility if commercially insured. Fifth, review injection technique with the prescriber or a nurse; bremelanotide is a subcutaneous auto-injector administered to the abdomen, thigh, or upper arm, not intravenously.

Auto-injector training videos are available through the Vyleesi manufacturer website. Michigan patients who experience significant nausea may discuss pre-treating with ondansetron 4 mg orally 30 minutes before injection; a 2020 pharmacokinetic analysis confirmed that ondansetron does not meaningfully alter bremelanotide plasma concentrations [11].

Women with a BMI <18.5 or over 40, cardiovascular disease, uncontrolled hypertension, or known hypersensitivity to bremelanotide should not use the drug per the FDA label [2]. Michigan prescribers should screen for these contraindications at the initial evaluation.

Patients should not use Vyleesi more than once per 24-hour period, and the label advises against using it more than about eight times per month based on study protocols, though the label does not impose a strict monthly maximum beyond the once-per-24-hours restriction [2].

Michigan-Specific Resources for Vyleesi Access

Several Michigan-specific resources can help with access and cost. The MDHHS Medicaid pharmacy benefit information is available at michigan.gov/mdhhs. Michigan's LARA pharmacy license lookup confirms 503A compounding pharmacy status. The Palatin Technologies patient assistance line (found on the Vyleesi prescribing information page at accessdata.fda.gov) handles savings card enrollment. NeedyMeds.org maintains a state-by-state database of patient assistance programs including Vyleesi.

Michigan also has a strong telehealth infrastructure; the Michigan Telehealth Network connects rural patients to licensed prescribers across the state. Patients in the Upper Peninsula or rural Lower Peninsula who lack local access to a sexual medicine specialist may find telehealth the most practical first step.

The average Michigan patient who qualifies for the Palatin savings card and has commercial insurance will pay a reduced co-pay, often under $100 per month. The average Michigan patient paying cash who uses a licensed 503A compounding pharmacy will pay approximately $140 per month. Michigan Medicaid enrollees who obtain PA approval pay no out-of-pocket cost for the drug itself under standard Medicaid pharmacy benefit rules, though visit co-pays may apply.